

March 13,2019

Department of Corporate Services

Bombay Stock Exchange, PhirozeJeejeebhoy Towers, Dalal Street, Mumbai - 400 001. Mr. Hari K.

Asst. Vice President - Operations National Stock Exchange of India Ltd. Exchange Plaza, BandraKurla Complex, Bandra (East), Mumbai - 400 051.

Ref: BSE Scrip Code - 506690 : NSE Symbol - UNICHEMIAB

Dear Sir,

Intimation under Regulation 30 of SEBI (Listing Obligations and Disclosure Reauirementsl Regulations, 2015.

Pursuant to Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, please find enclosed herewith the press release pertaining to receipt of ANDA approval from USFDA for Unichem's Allopurinol Tablets, USP 100 mg and 300 mg.

For Unichem Laboratories Limited

Sandip Ghume

Deputy Chief Financial Officer



Mumbai, Wednesday, March 13,2019

PRESS RELEASE

Unichem Laboratories Limited is pleased to announce that it has received ANDA approval for its Allopurinol Tablets, USP 100 mg and 300 mg from the United States Food and Drug Administration (USFDA) to market a generic version of ZYLOPRIM® (allopurinol) Tablets, which are indicated for the management of patients:

- 1. with signs and symptoms of primary or secondary gout (acute attacks, tophi, joint destruction, uric acid lithiasis, and/or nephropathy).
- 2. with leukemia, lymphoma and malignancies who are receiving cancer therapy which causes elevations of serum and urinary uric acid levels.
- 3. with recurrent calcium oxalate calculi whose daily uric acid excretion exceeds 800 mg/day in male patients and 750 mg/day in female patients.

The Product will be commercialized from Unichem's Ghaziabad Plant.

About Unichem Laboratories Limited

Unichem Laboratories Limited is an international, integrated, specialty pharmaceutical company. It manufactures and markets a large basket of pharmaceutical formulations as branded generics as well as generics in several markets across the world. In India, The Company has strong skills in product development, process chemistry and manufacturing complex API as well as dosage forms. More information about the Company can be found at www.unichemlabs.com

For more information please contact:

Ms. Neema Thakore Ph: +91-22-66888 404

E-mail: neema.thakore@unichemlabs.com

Disclaimer:

This press release includes forward-looking statements. We have based these forward-looking statements on our current expectations and projections about future events. Such statements involve known and unknown risks, uncertainties and other factors that may cause actual results to differ serially. Such factors include, but are not limited to, changes in local and global economic conditions, our ability to successfully implement our strategy, the market acceptance of and demand for our products, our growth and expansion, technological change and our exposure to market risks. By their nature, these expectations and projections are only estimates and could be materially different from actual results in the future.